Dr. Kenneth Saag
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Northwestern University Feinberg Medical School (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 394
Licensed in Alabama since 1998, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: Northwestern University Feinberg Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
AL license 22153 (first issued 1998; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 394
- Services billed
- 585
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 214 | 155 |
| Dxa bone density measurement of hip, pelvis, spine | 156 | 156 |
| Established patient office or other outpatient visit, 40-54 minutes | 30 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Established patient office or other outpatient visit, 20-29 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Birmingham, AL | 176 |
| Allopurinol Other prescribers in Birmingham, AL | 122 |
| Hydroxychloroquine Sulfate Other prescribers in Birmingham, AL | 92 |
| Methotrexate (methotrexate sodium) Other prescribers in Birmingham, AL | 79 |
| Enbrel Sureclick (etanercept) Other prescribers in Birmingham, AL | 69 |
| Rinvoq (upadacitinib) | 65 |
| Tramadol Hcl Other prescribers in Birmingham, AL | 35 |
| Febuxostat Other prescribers in Birmingham, AL | 33 |
| Gabapentin Other prescribers in Birmingham, AL | 29 |
| Pregabalin Other prescribers in Birmingham, AL | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 17 payments worth $20,249 in total to this clinician.
| Neurocrine Biosciences, Inc. | $15,006 |
|---|---|
| Chugai Pharmaceutical Co., LTD. | $3,450 |
| Kyowa Kirin, Inc. | $1,387 |
| Sobi, Inc | $164 |
| Aurinia Pharma U.S., Inc. | $125 |
| Amgen Inc. | $117 |
| Consulting Fee | $19,739 |
|---|---|
| Food and Beverage | $509 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Neurocrine Biosciences, Inc. Nov 18, 2025 | Consulting Fee CRENESSITY · Neuropsychiatry | $7,671 |
| Neurocrine Biosciences, Inc. Dec 4, 2025 | Consulting Fee CRENESSITY · Neuropsychiatry | $2,800 |
| Neurocrine Biosciences, Inc. Feb 4, 2025 | Consulting Fee CRENESSITY · Neuropsychiatry | $1,981 |
| Chugai Pharmaceutical Co., LTD. Jan 1, 2025 | Consulting Fee | $1,725 |
| Chugai Pharmaceutical Co., LTD. Aug 1, 2025 | Consulting Fee | $1,725 |
| Neurocrine Biosciences, Inc. Jul 9, 2025 | Consulting Fee CRENESSITY · Neuropsychiatry | $1,400 |
| Neurocrine Biosciences, Inc. Aug 11, 2025 | Consulting Fee CRENESSITY · Neuropsychiatry | $1,050 |
| Kyowa Kirin, Inc. Apr 24, 2025 | Consulting Fee | $832 |
| Kyowa Kirin, Inc. Nov 20, 2025 | Consulting Fee | $555 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 1 companies. The companies reported $3,082,769 in research payments for these studies, mostly to the institutions running them.
- A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - Improving Gout Care after an Emergency Department visit for Acute Gout
Amgen Inc. - P1b Uncontrolled Gout
Amgen Inc. - Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection,…
Amgen Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.